Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone

por Salvi, S, Casadio, V, Conteduca, V, Burgio, S L, Menna, C, Bianchi, E, Rossi, L, Carretta, E, Masini, C, Amadori, D, Calistri, D, Attard, G, De Giorgi, U
Publicado 2015

Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prost...

por Conteduca, V., Scarpi, E., Caroli, P., Salvi, S., Lolli, C., Burgio, S. L., Menna, C., Schepisi, G., Testoni, S., Gurioli, G., Paganelli, G., Casadio, V., Matteucci, F., De Giorgi, U.
Publicado 2017

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative b...

por Conteduca, V., Wetterskog, D., Sharabiani, M. T. A., Grande, E., Fernandez-Perez, M. P., Jayaram, A., Salvi, S., Castellano, D., Romanel, A., Lolli, C., Casadio, V., Gurioli, G., Amadori, D., Font, A., Vazquez-Estevez, S., González del Alba, A., Mellado, B., Fernandez-Calvo, O., Méndez-Vidal, M. J., Climent, M. A., Duran, I., Gallardo, E., Rodriguez, A., Santander, C., Sáez, M. I., Puente, J., Gasi Tandefelt, D., Wingate, A., Dearnaley, D., Demichelis, F., De Giorgi, U., Gonzalez-Billalabeitia, E., Attard, G.
Publicado 2017